Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBPY9Z)

• Drug Name: MBG453 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myelodysplastic syndrome	2A37	Phase 3	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]

• Cross-matching ID: TTD Drug ID: DMBPY9Z

Molecule-Related Drug Atlas

Drug(s) Targeting Hepatitis A virus cellular receptor 2 (TIM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO7121661	DM8A120	Esophageal squamous cell carcinoma	2E60.1	Phase 2	[3]
GSK4069889	DMV6SNU	Non-small-cell lung cancer	2C25	Phase 2	[4]
AZD7789	DMOIHWI	Hodgkin lymphoma	2B30	Phase 2	[5]
TB006	DMKN524	Alzheimer disease	8A20	Phase 2	[6]
BGB-A425	DMI42Q0	Non-small-cell lung cancer	2C25	Phase 1/2	[7]
LY3415244	DM5QO1A	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
LY3321367	DMD51GC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
Sym023	DMV3L62	Lymphoma	2A80-2A86	Phase 1	[9]
INCAGN2390	DM5SO1T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis A virus cellular receptor 2 (TIM3)	TT1RWL7	HAVR2_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04266301) Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [5] Clinical pipeline report, company report or official report of AstraZeneca
• [6] Clinical pipeline report, company report or official report of TrueBinding
• [7] Clinical pipeline report, company report or official report of BeiGene.
• [8] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
• [9] Clinical pipeline report, company report or official report of Symphogen.
• [10] Clinical pipeline report, company report or official report of Agenus.